Experimental Therapeutics at Mount Sinai team up with Regeneron on antibody research

THE EXPERIMENTAL THERAPEUTICS INSTITUTE at the Icahn School of Medicine at Mount Sinai and Regeneron Pharmaceuticals Inc. entered into an agreement with the goal of accelerating the discovery of fully-human antibodies directed against therapeutic targets being researched by Mount Sinai investigators.

Regeneron will provide the ETI with access to VelocImmune technology and potential financial support to use the company’s proprietary antibody discovery platform to generate antibodies against targets of interest and explore potential therapeutic applications for human disease.

ETI will undertake preclinical research and Regeneron has an exclusive option to negotiate a license to the antibody for future clinical development and commercialization.

Developed by Regeneron scientists, VelocImmune is a genetic engineering platform that enables the fast and efficient creation of superior fully-human monoclonal antibodies for drug development.

DOWNLOAD THE PDF

Table of Contents

YOU MAY BE INTERESTED IN

Clinical

How MD Anderson and Texas Children’s made plans to build a $1 billion pediatric cancer hospital—one of the world’s largest

The windows down the hall from the operating room scrub sinks at MD Anderson Cancer Center look out at the tower of Texas Children’s Hospital.

June 27, 2025

Vol.51 No.25

By Paul Goldberg

Capitol Hill

At House hearing, Democrats clash with RFK Jr. over “radical obstruction of congressional oversight,” vaccine policies
Rep. Lori Trahan: “People are going to die”

Secretary of the U.S. Department of Health and Human Services Robert F. Kennedy Jr. appeared before the House Energy and Commerce Subcommittee on Health to defend the HHS fiscal year 2026 budget proposal, and faced criticism from several Democratic lawmakers on what they described as a lack of transparency and scientific rigor in the agency’s recent decisions.

June 27, 2025

Vol.51 No.25

By Claire Marie Porter

Guest Editorial

Building cancer care resilience through international observerships: Lessons from Ukraine

The full-scale Russian invasion of Ukraine has devastated the Ukrainian healthcare infrastructure, disrupting cancer care, halting clinical trials, and compounding long-standing systemic challenges. Even before the war, Ukraine’s oncology system faced major constraints: Limited access to radiotherapy equipment, outdated chemotherapy supply chains, and workforce shortages. The invasion intensified these issues—cancer hospitals were damaged, warehouses destroyed,...

June 27, 2025

Vol.51 No.25

By Nataliya Kovalchuk, Andriy Beznosenko, Vitaliy Y. Poylin, Rostyslav Semikov, Arman Kacharian, Douglas Davis, Nataliya Uboha, Natalka Suchowerska, Viktor Iakovenko, Jacqueline Hart, Mark Poznansky, Darya Kizub and Nelya Melnitchouk

Clinical Trials & Tribulations

As cancer patients use AI chatbots, dangers lurk—but new safeguards can help

Patients affected by cancer are increasingly turning to artificial intelligence-powered chatbots, such as ChatGPT and Gemini, for answers to pressing health questions. These tools, available around the clock and free from geographic or scheduling constraints, are appealing when access to medical professionals is limited by financial, language, logistical, or emotional barriers.

June 27, 2025

Vol.51 No.25

By Ghulam Rasool, Brian D. Gonzalez and Katherine Chung-Bridges

Cancer Policy

Jacqueline Corrigan-Curay to retire as acting head of CDER at FDA

Jacqueline Corrigan-Curay, the acting director of the Center for Drug Evaluation and Research wrote in an email to colleagues that she will be retiring from the agency in July.

June 27, 2025

Vol.51 No.25

By Claire Marie Porter

Cancer Policy

RFK Jr.’s new committee votes on vaccine recommendations, despite Sen. Cassidy’s call for meeting delay

Sen. Bill Cassidy (R-LA), a key Senate health leader, June 23 called for the meeting of the Advisory Committee on Immunization Practices to be delayed, citing concerns over the committee members’ lack of directly relevant experience and their potential bias against some vaccines.

June 27, 2025

Vol.51 No.25

By Claire Marie Porter and Jacquelyn Cobb

Experimental Therapeutics at Mount Sinai team up with Regeneron on antibody research

YOU MAY BE INTERESTED IN

How MD Anderson and Texas Children’s made plans to build a $1 billion pediatric cancer hospital—one of the world’s largest

At House hearing, Democrats clash with RFK Jr. over “radical obstruction of congressional oversight,” vaccine policies
Rep. Lori Trahan: “People are going to die”

Building cancer care resilience through international observerships: Lessons from Ukraine

As cancer patients use AI chatbots, dangers lurk—but new safeguards can help

Jacqueline Corrigan-Curay to retire as acting head of CDER at FDA

RFK Jr.’s new committee votes on vaccine recommendations, despite Sen. Cassidy’s call for meeting delay

Renew today!

Subscriber content

Never miss an issue!

Login

Experimental Therapeutics at Mount Sinai team up with Regeneron on antibody research

YOU MAY BE INTERESTED IN

How MD Anderson and Texas Children’s made plans to build a $1 billion pediatric cancer hospital—one of the world’s largest

At House hearing, Democrats clash with RFK Jr. over “radical obstruction of congressional oversight,” vaccine policiesRep. Lori Trahan: “People are going to die”

Building cancer care resilience through international observerships: Lessons from Ukraine

As cancer patients use AI chatbots, dangers lurk—but new safeguards can help

Jacqueline Corrigan-Curay to retire as acting head of CDER at FDA

RFK Jr.’s new committee votes on vaccine recommendations, despite Sen. Cassidy’s call for meeting delay

Never miss an issue!

Login

At House hearing, Democrats clash with RFK Jr. over “radical obstruction of congressional oversight,” vaccine policies
Rep. Lori Trahan: “People are going to die”